PharmacoEconomics & Outcomes News 784, p29 - 12 Aug 2017 Treatment patterns and costs for advanced GC vary in Mexico Treatment patterns and costs in patients with advanced or metastatic gastric cancer (GC) vary in Mexico, according to findings of an Eli Lilly and Company-affiliated chart review published in PharmacoEconomics - Open. Investigators reviewed Data Report File data for 180 adult patients at three tertiary centres who were diagnosed with advanced or metastatic GC between January 2009 and January 2015, received a first-line fluoropyrimidine and platinum regimen, and were followed up for at least 3 months after discontinuing first-line treatment. Direct medical costs were estimated from a payer perspective. In total, 16 first-line chemotherapy regimens and 19 second-line regimens were used. Overall, 83.9% of patients received second-line chemotherapy, 28.3% received third-line chemotherapy, and less than 10% of patients received over three lines of chemotherapy. Supportive care during in first- versus second-line chemotherapy included pain treatment (12.2% vs 7.9%), nutritional support (3.3% vs 1.3%), radiotherapy (6.1% vs 16.6%) and transfusions (13.3% vs 10.6%). Based on Mexican Institute of Social Security tariffs, the average total direct cost for first-line and second-line therapy was $1230 and $1192 per patient-month, respectively, primarily due to administration costs and drug acquisition costs. "Understanding GC treatment patterns in Mexico will help measure the impact of new innovations in treatment practice and create opportunities to harmonize treatment options," said the authors. * 2015 US dollars Quintana M, et al. Resources and Costs Associated with the Treatment of Advanced and Metastatic Gastric Cancer in the Mexican Public Sector: A Patient Chart Review. PharmacoEconomics-Open : 31 Jul 2017. Available from: URL: http://dx.doi.org/10.1007/s41669-017-0043-2 803262565 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784
PharmacoEconomics & Outcomes News – Springer Journals
Published: Aug 12, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud